Full text is available at the source.
Abstract
The review highlights a shift from traditional vaccine development to a versatile, programmable therapeutic platform based on messenger RNA.
- mRNA technology has transitioned from emergency response applications to potential use in chronic disease management and precision oncology.
- Next-generation delivery vehicles are being developed to enhance tissue targeting and reduce systemic reactogenicity compared to current Lipid Nanoparticles.
- The safety profiles of mRNA modalities are compared favorably to DNA-based therapies, particularly in acute and personalized medical contexts.
- Current gaps in manufacturing scalability and regulatory harmonization may hinder the widespread adoption of mRNA technologies.
- Patent concentration among leading industry players is impacting global innovation and market accessibility in the mRNA landscape.
Simplified